Amgen Newsroom

Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today

Kevin Travers16:22 ET

FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development

Seeking Alpha12:52 ET

CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock

Kevin TraversJan 6 10:52 ET

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

Yahoo FinanceJan 6 07:51 ET

Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK

ReutersJan 6 04:28 ET

Amgen's IMDYLLTRA▼ (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

BusinesswireJan 6 04:25 ET

These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively

Simply Wall StJan 4 09:08 ET

Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz

Kevin TraversJan 3 16:19 ET

Friday? More Like Grinch Day | Wall Street Today

Kevin TraversJan 3 16:02 ET

Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer

Seeking AlphaJan 3 11:21 ET

Santa Claus Came Without Rallying the Troops | Live Stock

Kevin TraversJan 3 10:45 ET

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo FinanceJan 3 09:00 ET

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

BenzingaJan 3 07:39 ET

CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong StocksJan 3 03:36 ET

Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310

Moomoo NewsJan 2 07:32 ET · Ratings

Amgen Is Maintained at Overweight by Piper Sandler

Dow JonesJan 2 07:01 ET · Ratings

Analyst Expectations For Amgen's Future

BenzingaJan 2 07:00 ET

Amgen Analyst Ratings

BenzingaJan 2 06:48 ET · Ratings

Express News | Amgen Inc : Piper Sandler Cuts Target Price to $310 From $344

ReutersJan 2 00:13 ET

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025

BenzingaDec 31, 2024 10:45 ET